FDA Approves Lilly Cancer Drug Combo
The US FDA approved Eli Lilly's drug combination to treat adults with advanced breast cancer. The therapy combines Inluriyo and Verzenio to help patients whose cancer has progressed after hormone treatment.
Xurve View
Insights:
Xurve View
Eli Lilly & Co has won U.S. Food and Drug Administration approval for a new drug combination to treat advanced breast cancer. The treatment targets adult patients with metastatic disease carrying an ESR1 mutation.
